Sign in Subscribe
Cancer

Silencing Daxx Enhances Anti-Tumor Activity through Enhanced Viral Replication and Cellular Arrest

Strategic Insights

— 1 min read

Researchers from Yonsei University have conducted a study to determine the effect of Daxx downregulation on anti-tumorigenesis induced by oncolytic adenovirus armed with TRAIL or TRAIL/shRNA of Bcl-xL genes. The study found that Daxx downregulation increases the anti-tumorigenic activity through enhancement of viral replication and cellular arrest with combination of TRAIL/shBcl-xL-induced apoptosis. This breakthrough research has significant implications for the development of novel cancer therapies.

Key Takeaways:

  • The study showed that Daxx downregulation enhances anti-tumor activity through increased viral replication and cellular arrest.
  • The combination of TRAIL/shBcl-xL-induced apoptosis and oncolytic adenovirus expression resulted in enhanced cytotoxic cell death and viral replication.
  • Daxx downregulation stimulated cellular arrest through p21/p53 accumulation.
  • The study concluded that Daxx downregulation is essential for increasing anti-tumor activity through enhanced viral replication and cellular arrest.
  • The research highlights the importance of understanding the role of Daxx in regulating viral replication and cellular arrest.
  • The study underscores the potential of oncolytic adenoviruses as a cancer therapy and the need for further investigation into the mechanisms of Daxx downregulation.

Statistics:

  • 27(6):1214-1224: The page number and publication information of the study published in Cellular Signalling.
  • 2015: The year of publication of the study.
  • 360 Park Ave South, New York, NY 10010-1710, USA: The address of Elsevier Science Inc, the publisher of Cellular Signalling.

Sources:

  • Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest. Cellular Signalling, 2015;27(6):1214-1224.
  • Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA.
  • Yonsei University, Coll Med, Severance Biomed Sci Inst, Seoul, South Korea.

Read more